Up
News: Fibrogen announced that the new clinical drug application for FG-3165, a monoclonal antibody targeting Galectin-9, has been approved by the FDA for treating solid tumors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
